1
|
Liu YS, Song JW, Zhong WX, Yuan MH, Guo YR, Peng C, Guo L, Guo YP. Dual Drug-Loaded Nanoliposomes Encapsulating Curcumin and 5-Fluorouracil with Advanced Medicinal Applications: Self-Monitoring and Antitumor Therapy. Molecules 2023; 28:molecules28114353. [PMID: 37298829 DOI: 10.3390/molecules28114353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Accepted: 05/19/2023] [Indexed: 06/12/2023] Open
Abstract
Due to the presence of physiological barriers, it is difficult to achieve the desired therapeutic efficacy of drugs; thus, it is necessary to develop an efficient drug delivery system that enables advanced functions such as self-monitoring. Curcumin (CUR) is a naturally functional polyphenol whose effectiveness is limited by poor solubility and low bioavailability, and its natural fluorescent properties are often overlooked. Therefore, we aimed to improve the antitumor activity and drug uptake monitoring by simultaneously delivering CUR and 5-Fluorouracil (5-FU) in the form of liposomes. In this study, dual drug-loaded liposomes (FC-DP-Lip) encapsulating CUR and 5-FU were prepared by the thin-film hydration method; their physicochemical properties were characterized; and their biosafety, drug uptake distribution in vivo, and tumor cell toxicity were evaluated. The results showed that the nanoliposome FC-DP-Lip showed good morphology, stability, and drug encapsulation efficiency. It showed good biocompatibility, with no side effects on zebrafish embryonic development. In vivo uptake in zebrafish showed that FC-DP-Lip has a long circulation time and presents gastrointestinal accumulation. In addition, FC-DP-Lip was cytotoxic against a variety of cancer cells. This work showed that FC-DP-Lip nanoliposomes can enhance the toxicity of 5-FU to cancer cells, demonstrating safety and efficiency, and enabling real-time self-monitoring functions.
Collapse
Affiliation(s)
- Yu-Shi Liu
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
| | - Jia-Wen Song
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
| | - Wen-Xiao Zhong
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
| | - Ming-Hao Yuan
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
| | - Yu-Rou Guo
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
| | - Cheng Peng
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
| | - Li Guo
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
| | - Yi-Ping Guo
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
| |
Collapse
|
2
|
Wu X, Guo H, Zhao J, Wei Y, Li YX, Pang HB. Identification of an ALK-2 inhibitor as an agonist for intercellular exchange and tumor delivery of nanomaterial. ADVANCED THERAPEUTICS 2023; 6:2200173. [PMID: 36818419 PMCID: PMC9937035 DOI: 10.1002/adtp.202200173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2022] [Indexed: 11/08/2022]
Abstract
Inefficient extravasation and penetration in solid tissues hinder the clinical outcome of nanoparticles (NPs). Recent studies have shown that the extravasation and penetration of NPs in solid tumor was mostly achieved via an active transcellular route. For this transport process, numerous efforts have been devoted to elucidate the endocytosis and subcellular trafficking of NPs. However, how they exit from one cell and re-enter into neighboring ones (termed intercellular exchange) remains poorly understood. We previously developed cellular assays that exclusively quantify the intercellular exchange of NPs in vitro. Our study showed that a significant portion of NPs are transferred inside extracellular vesicles (EVs). Pharmacological inhibition of EV biogenesis significantly reduced the tumor accumulation and vascular penetration of both inorganic and organic NPs in vivo. Intrigued by this result, we performed here a manual chemical screen with our assay, which identified that LDN-214117 (an inhibitor for activin receptor-like kinase-2, ALK-2) is an agonist of NP intercellular exchange. We further showed that LDN-214117 regulates the intercellular exchange by increasing the EV biogenesis. Mechanistic investigation showed that LDN-214117 functions via BMP (bone morphogenetic protein)-MAPK (mitogen-activated protein kinase) signaling pathway to increase EV biogenesis. We further demonstrated that LDN-214117 treatment in vivo enhanced the tumor accumulation and vascular penetration of a variety of NPs in multiple tumor models, which improves their antitumor efficacy. Overall, we showcase here the identification of a novel chemical compound with our intercellular exchange assays to modulate EV biogenesis and EV-mediated transport, thus boosting up the delivery and therapeutic efficacy of nanomaterial.
Collapse
Affiliation(s)
- Xian Wu
- Department of Pharmaceutics, University of Minnesota, Minneapolis, MN, USA
| | - Hong Guo
- Department of Pharmaceutics, University of Minnesota, Minneapolis, MN, USA
| | - Jiaqi Zhao
- Department of Pharmaceutics, University of Minnesota, Minneapolis, MN, USA
| | - Yushuang Wei
- Department of Pharmaceutics, University of Minnesota, Minneapolis, MN, USA
| | - Yue-Xuan Li
- Department of Pharmaceutics, University of Minnesota, Minneapolis, MN, USA
| | - Hong-Bo Pang
- Department of Pharmaceutics, University of Minnesota, Minneapolis, MN, USA
| |
Collapse
|
3
|
Dana PM, Sadoughi F, Reiter RJ, Mohammadi S, Heidar Z, Mirzamoradi M, Asemi Z. Melatonin as an adjuvant treatment modality with doxorubicin [Biochimie 200 (2022) 1-7]. Biochimie 2022; 200:1-7. [PMID: 35569703 DOI: 10.1016/j.biochi.2022.05.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2022] [Revised: 04/30/2022] [Accepted: 05/09/2022] [Indexed: 01/12/2023]
Affiliation(s)
- Parisa Maleki Dana
- Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, I.R, Iran
| | - Fatemeh Sadoughi
- Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, I.R, Iran
| | - Russel J Reiter
- Department of Cell Systems and Anatomy, UT Health. Long School of Medicine, San Antonio, TX, USA
| | - Sotoudeh Mohammadi
- Clinical Research Development Center, Mahdiyeh Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Zahra Heidar
- Clinical Research Development Center, Mahdiyeh Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
| | - Masoumeh Mirzamoradi
- Clinical Research Development Center, Mahdiyeh Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Zatollah Asemi
- Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, I.R, Iran
| |
Collapse
|
4
|
Maleki Dana P, Sadoughi F, J Reiter R, Mohammadi S, Heidar Z, Mirzamoradi M, Asemi Z. Melatonin as an adjuvant treatment modality with doxorubicin. Biochimie 2022; 202:49-55. [PMID: 35752222 DOI: 10.1016/j.biochi.2022.06.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Combination chemotherapy seems to be a beneficial choice for some cancer patients particularly when the drugs target different processes of oncogenesis; patients treated with combination therapies sometimes have a better prognosis than those treated with single drug chemotherapy. However, research has shown that this is not always the case, and this approach may only increase toxicity without having a significant effect in augmenting the antitumor actions of the drugs. Doxorubicin (Dox) is one of the most common chemotherapy drugs used to treat many types of cancer, but it also has serious side effects, such as cardiotoxicity, skin necrosis, testicular toxicity, and nephrotoxicity. Many studies have examined the efficiacy of melatonin (MLT) as an anticancer agent. In fact, MLT is an anti-cancer agent that has various functions in inhibiting cancer cell proliferation, inducing apoptosis, and suppressing metastasis. Herein, we provide a comprehensive evaluation of the literature concerned with the role of MLT as an adjuvant in Dox-based chemotherapies and discuss how MLT may enhance the antitumor effects of Dox (e.g., by inducing apoptosis and suppressing metastasis) while rescuring other organs from its adverse effects, such as cardio- and nephrotoxicity.
Collapse
Affiliation(s)
- Parisa Maleki Dana
- Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, I.R. Iran.
| | - Fatemeh Sadoughi
- Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, I.R. Iran.
| | - Russel J Reiter
- Department of Cell Systems and Anatomy, UT Health. Long School of Medicine, San Antonio, TX, USA.
| | - Sotoudeh Mohammadi
- Clinical Research Development Center, Mahdiyeh Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
| | - Zahra Heidar
- Clinical Research Development Center, Mahdiyeh Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
| | - Masoumeh Mirzamoradi
- Clinical Research Development Center, Mahdiyeh Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
| | - Zatollah Asemi
- Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, I.R. Iran.
| |
Collapse
|
5
|
Basu A, Singh R, Gupta S. Bacterial infections in cancer: A bilateral relationship. WILEY INTERDISCIPLINARY REVIEWS. NANOMEDICINE AND NANOBIOTECHNOLOGY 2022; 14:e1771. [PMID: 34994112 DOI: 10.1002/wnan.1771] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/01/2021] [Revised: 10/09/2021] [Accepted: 11/12/2021] [Indexed: 12/15/2022]
Abstract
Bacteria share a long commensal relationship with the human body. New findings, however, continue to unravel many complexities associated with this old alliance. In the past decades, the dysbiosis of human microbiome has been linked to tumorigenesis, and more recently to spontaneous colonization of existing tumors. The topic, however, remains open for debate as the claims for causative-prevailing dual characteristics of bacteria are mostly based on epidemiological evidence rather than robust mechanistic models. There are also no reviews linking the collective impact of bacteria in tumor microenvironments to the efficacy of cancer drugs, mechanisms of pathogen-initiated cancer and bacterial colonization, personalized nanomedicine, nanotechnology, and antimicrobial resistance. In this review, we provide a holistic overview of the bilateral relationship between cancer and bacteria covering all these aspects. Our collated evidence from the literature does not merely categorize bacteria as cancer causative or prevailing agents, but also critically highlights the gaps in the literature where more detailed studies may be required to reach such a conclusion. Arguments are made in favor of dual drug therapies that can simultaneously co-target bacteria and cancer cells to overcome drug resistance. Also discussed are the opportunities for leveraging the natural colonization and remission power of bacteria for cancer treatment. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Emerging Technologies.
Collapse
Affiliation(s)
- Abhirup Basu
- Department of Chemical Engineering, Indian Institute of Technology, Delhi, India
| | - Rohini Singh
- Department of Chemical Engineering, Indian Institute of Technology, Delhi, India
| | - Shalini Gupta
- Department of Chemical Engineering, Indian Institute of Technology, Delhi, India
| |
Collapse
|
6
|
Bollareddy SR, Krishna V, Roy G, Dasari D, Dhar A, Venuganti VVK. Transfersome Hydrogel Containing 5-Fluorouracil and Etodolac Combination for Synergistic Oral Cancer Treatment. AAPS PharmSciTech 2022; 23:70. [PMID: 35132496 DOI: 10.1208/s12249-022-02221-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2021] [Accepted: 01/17/2022] [Indexed: 11/30/2022] Open
Abstract
Oral cancer is one of the most common malignancies with an increased rate of incidence. 5-Fluorouracil (5FU) is an effective chemotherapeutic indicated for oral cancer treatment. Etodolac (Et), a cyclooxygenase-2 inhibitor, can be used as an adjuvant agent to sensitize cancer cells to chemotherapy. The aim of this work was to prepare and characterize 5FU and Et dual drug-loaded transfersomes to treat oral cancer. Transfersomes were prepared by thin-film hydration method and characterized for the average particle size and zeta-potential using dynamic light scattering and scanning electron microscopy techniques. The prepared transfersomes were further characterized for their drug loading, entrapment efficiencies using amicon centrifuge tubes and drug release behavior using cellulose membrane. The synergistic activity of dual drug-loaded transfersomes was studied in FaDu oral cancer cells. Results showed that the average particle size, polydispersity index, and zeta potential were 91±6.4 nm, 0.28±0.03, and (-)46.9±9.5 mV, respectively, for 5FU- and Et (1:1)-loaded transfersomes. The highest encapsulation efficiency achieved was 36.9±3.8% and 79.8±6.4% for 5FU and Et (1:1), respectively. Growth inhibition studies in FaDu cells using different concentrations of 5FU and Et showed a combination index of 0.36, indicating a synergistic effect. The FaDu cell uptake of drug-loaded transfersomes was significantly (p<0.05) greater than that of free drugs. The transfersome hydrogel made of HPMC (2% w/w) showed similar flux, lag time, and permeation coefficient as that of drug-loaded transfersomes across excised porcine buccal tissue. In conclusion, 5FU and Et transfersome hydrogel can be developed for localized delivery to treat oral cancer.
Collapse
|
7
|
Zhang L, Zhang S, Jiang M, Lu L, Ding Y, Ma N, Zhao Y, Xuchen S, Zhang N. Novel Timosaponin AIII-Based Multifunctional Liposomal Delivery System for Synergistic Therapy Against Hepatocellular Carcinoma Cancer. Int J Nanomedicine 2021; 16:5531-5550. [PMID: 34429598 PMCID: PMC8379713 DOI: 10.2147/ijn.s313759] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Accepted: 06/24/2021] [Indexed: 12/12/2022] Open
Abstract
Introduction As high cholesterol level has been reported to be associated with cancer cell growth and cholesterol is vulnerable to oxidation, the conventional liposomes including cholesterol in the formulation seem to be challenged. Timosaponin AIII (TAIII), as a steroid saponin from Anemarrhena asphodeloides Bunge, possesses a similar structure with cholesterol and exhibits a wide range of antitumor activities, making it possible to develop a TAIII-based liposome where TAIII could potentially stabilize the phospholipid bilayer as a substitution of cholesterol and work as a chemotherapeutic drug as well. Meanwhile, TAIII could enhance the uptake of doxorubicin hydrochloride (DOX) in human hepatocellular carcinoma (HCC) cells and exhibit synergistic effect. Thus, we designed a novel thermally sensitive multifunctional liposomal system composed of TAIII and lipids to deliver DOX for enhanced HCC treatment. Methods The synergistic effects of DOX and TAIII were explored on HCC cells and the tumor inhibition rate of TAIII-based liposomes carrying DOX was evaluated on both subcutaneous and orthotopic transplantation tumor models. TAIII-based multifunctional liposomes were characterized. Results Synergistic HCC cytotoxicity was achieved at molar ratios of 1:1, 1:2 and 1:4 of DOX/TAIII. TAIII-based liposomes carrying a low DOX dose of 2 mg/kg exhibited significantly enhanced antitumor activity than 5 mg/kg of DOX without detected cardiotoxicity on both subcutaneous and orthotopic transplantation tumor models. TAIII-based liposomes were characterized with smaller size than cholesterol liposomes but exhibited favorable stability. Mild hyperthermia generated by laser irradiation accelerated the release of DOX and TAIII from liposomes at tumor site, and cell permeability of TAIII enhanced uptake of DOX in HCC cells. Conclusion The innovative application of TAIII working as bilayer stabilizer and chemotherapeutic drug affords a stable multifunctional liposomal delivery system for synergistic therapy against HCC, which may be referred for the development of other types of saponins with similar property.
Collapse
Affiliation(s)
- Lijuan Zhang
- School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China
| | - Shengan Zhang
- School of Basic Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China
| | - Min Jiang
- School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China
| | - Lu Lu
- Experiment Center for Teaching and Learning, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China
| | - Yue Ding
- Experiment Center for Teaching and Learning, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China
| | - Ninghui Ma
- School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China
| | - Yuan Zhao
- Center of Science and Technology, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China
| | - Sihan Xuchen
- School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China
| | - Nailian Zhang
- School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China
| |
Collapse
|
8
|
Sathiyaseelan A, Saravanakumar K, Mariadoss AVA, Wang MH. pH-controlled nucleolin targeted release of dual drug from chitosan-gold based aptamer functionalized nano drug delivery system for improved glioblastoma treatment. Carbohydr Polym 2021; 262:117907. [PMID: 33838795 DOI: 10.1016/j.carbpol.2021.117907] [Citation(s) in RCA: 52] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2020] [Revised: 12/19/2020] [Accepted: 03/03/2021] [Indexed: 12/18/2022]
Abstract
This study developed the pH, and over-expressed nucleolin receptor responsive nano-drug delivery system (nDDS) composed by bio-synthesized gold nanoparticles (Au NPs), chitosan (CS) with aptamer (Apt) to deliver the 5-fluorouracil (5FU) and doxorubicin (Dox) for the improved glioblastoma treatment. The characterization results demonstrated that Apt-Dox-CS-Au-5FU NPs were monodispersed in nature with an average hydrodynamic particle size of 196.2 ± 2.89 nm and zeta potential of 16.26 ± 0.51 mV. The drug release, drug encapsulation efficiency (DEE), and loading efficiency (DLE) were measured by HPLC. The pH-responsive dual drug release was instigated the higher glioblastoma cell death instead of the single drug release through G0/G1 phase cell cycle arrest. In addition, the internalization of Apt-Dox-CS-Au-5FU NPs in cell organelles was affirmed by bio-TEM analysis. Overall, this work revealed the newly designed drug-loaded smart nDDS improved the glioblastoma treatments.
Collapse
Affiliation(s)
- Anbazhagan Sathiyaseelan
- Department of Bio-Health Convergence, Kangwon National University, Chuncheon, 200-701, Republic of Korea.
| | - Kandasamy Saravanakumar
- Department of Bio-Health Convergence, Kangwon National University, Chuncheon, 200-701, Republic of Korea.
| | | | - Myeong-Hyeon Wang
- Department of Bio-Health Convergence, Kangwon National University, Chuncheon, 200-701, Republic of Korea.
| |
Collapse
|
9
|
Li J, Zhou S, Yu J, Cai W, Yang Y, Kuang X, Liu H, He Z, Wang Y. Low dose shikonin and anthracyclines coloaded liposomes induce robust immunogenetic cell death for synergistic chemo-immunotherapy. J Control Release 2021; 335:306-319. [PMID: 34081995 DOI: 10.1016/j.jconrel.2021.05.040] [Citation(s) in RCA: 36] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2021] [Revised: 05/20/2021] [Accepted: 05/29/2021] [Indexed: 12/14/2022]
Abstract
Chemo-immunotherapy based on immunogenic cell death (ICD) is a promising strategy for cancer therapy. However, the effective ICD requires a high dosage of ICD stimulus, which could be associated to a dose-dependent toxicity. Therefore, in this study, a liposome remote-loaded with shikonin (a potent ICD stimulus) was developed, with the ability to effectively induce ICD at high dosage in vivo. However, a hepatotoxic effect was observed. To circumvent this problem, shikonin was combined with the anthracycline mitoxantrone or doxorubicin to develop co-loaded liposomes inducing a synergistic ICD effect and cytotoxicity to tumor cells. Cytotoxicity and uptake experiment in vitro were performed to analyze the optimal synergistic ratio of shikonin and anthracyclines based on a "formulated strategy". Interestingly, copper mediated co-loaded liposomes resulted in a pH and GSH dual-responsive release property. More importantly, pharmacokinetics and tumor biodistribution studies revealed an outstanding capacity of ratiometric delivery of dual drugs. Thus, the dual-loaded liposome enhanced the antitumor effect by the stimulation of a robust immune response at lower doses of the drugs with a higher safety compared to single-loaded liposomes. Summarized, the current work provided a reference for a rational design and development of liposomal co-delivery system of drugs and ICD-induced chemo-immunotherapy, and established a potential clinical application of shikonin-based drug combinations as a new chemo-immunotherapeutic strategy for cancer treatment.
Collapse
Affiliation(s)
- Jinbo Li
- Wuya College of Innovation, Shenyang Pharmaceutical University, Wenhua Road, Shenyang 110016, China
| | - Shuang Zhou
- Wuya College of Innovation, Shenyang Pharmaceutical University, Wenhua Road, Shenyang 110016, China
| | - Jiang Yu
- Wuya College of Innovation, Shenyang Pharmaceutical University, Wenhua Road, Shenyang 110016, China
| | - Wenxu Cai
- Wuya College of Innovation, Shenyang Pharmaceutical University, Wenhua Road, Shenyang 110016, China
| | - Yinxian Yang
- Wuya College of Innovation, Shenyang Pharmaceutical University, Wenhua Road, Shenyang 110016, China
| | - Xiao Kuang
- Wuya College of Innovation, Shenyang Pharmaceutical University, Wenhua Road, Shenyang 110016, China
| | - Hongzhuo Liu
- Wuya College of Innovation, Shenyang Pharmaceutical University, Wenhua Road, Shenyang 110016, China
| | - Zhonggui He
- Wuya College of Innovation, Shenyang Pharmaceutical University, Wenhua Road, Shenyang 110016, China
| | - Yongjun Wang
- Wuya College of Innovation, Shenyang Pharmaceutical University, Wenhua Road, Shenyang 110016, China.
| |
Collapse
|
10
|
Phenylboronic acid-functionalized co-delivery micelles with synergistic effect and down-regulation of HIF-1alpha to overcome multidrug resistance. J Drug Deliv Sci Technol 2021. [DOI: 10.1016/j.jddst.2021.102346] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
11
|
Wang S, Gou J, Wang Y, Tan X, Zhao L, Jin X, Tang X. Synergistic Antitumor Efficacy Mediated by Liposomal Co-Delivery of Polymeric Micelles of Vinorelbine and Cisplatin in Non-Small Cell Lung Cancer. Int J Nanomedicine 2021; 16:2357-2372. [PMID: 33790554 PMCID: PMC7997865 DOI: 10.2147/ijn.s290263] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2020] [Accepted: 02/27/2021] [Indexed: 12/24/2022] Open
Abstract
PURPOSE Non-small cell lung cancer (NSCLC) is an aggressive tumor with high mortality and poor prognosis. In this study, we designed a liposome encapsulating polymeric micelles (PMs) loaded with vinorelbine (NVB) and cis-diamminedichloroplatinum (II) (cisplatin or CDDP) for the treatment of NSCLC. MATERIALS AND METHODS Sodium poly(α-l-glutamic acid)-graft-methoxy-polyethylene glycol (PLG-G-PEG5K) was used to prepare NVB-loaded NVB-PMs and CDDP-loaded CDDP-PMs that were co-encapsulated into liposomes by a reverse evaporation method, yielding NVB and CDDP co-delivery liposomes (CoNP-lips) composed of egg phosphatidyl lipid-80/cholesterol/DPPG/DSPE-mPEG2000 at a molar ratio of 52:32:14:2. The CoNP-lips were characterized in terms of particle size, zeta potential, drug content, encapsulation efficiency, and structural properties. Drug release by the CoNP-lips as well as their stability and cytotoxicity was evaluated in vitro, and their antitumor efficacy was assessed in a mouse xenograft model of Lewis lung carcinoma cell-derived tumors. RESULTS CoNP-lips had a spherical shape with uniform size distribution; the average particle size was 162.97±9.06 nm, and the average zeta potential was -13.02±0.22 mV. In vitro cytotoxicity analysis and the combination index demonstrated that the CoNP-lips achieved a synergistic cytotoxic effect at an NVB:CDDP weight ratio of 2:1 in an NSCLC cell line. There was sustained release of both drugs from CoNP-lips. The pharmacokinetic analysis showed that CoNP-lips had a higher plasma half-life than NP solution, with 6.52- and 8.03-fold larger areas under the receiver operating characteristic curves of NVB and CDDP. CoNP-lips showed antitumor efficacy in tumor-bearing C57BL/6 mice and drug accumulation in tumors via the enhanced permeability and retention effect. CONCLUSION CoNP-lips are a promising formulation for targeted therapy in NSCLC.
Collapse
Affiliation(s)
- Shuhang Wang
- Department of Pharmaceutics, College of Pharmacy Sciences, Jilin University, Changchun, 130021, Jilin, People’s Republic of China
| | - Jingxin Gou
- Department of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang, 110016, People’s Republic of China
| | - Yue Wang
- Department of Pharmaceutics, College of Pharmacy Sciences, Jilin University, Changchun, 130021, Jilin, People’s Republic of China
| | - Xinyi Tan
- Department of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang, 110016, People’s Republic of China
| | - Linxuan Zhao
- Department of Pharmaceutics, College of Pharmacy Sciences, Jilin University, Changchun, 130021, Jilin, People’s Republic of China
| | - Xiangqun Jin
- Department of Pharmaceutics, College of Pharmacy Sciences, Jilin University, Changchun, 130021, Jilin, People’s Republic of China
| | - Xing Tang
- Department of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang, 110016, People’s Republic of China
| |
Collapse
|
12
|
Fang Q, Xu X, Yang L, Xue Y, Cheng X, Wang X, Tang R. Self-assembled 5-fluorouracil-cinnamaldehyde nanodrugs for greatly improved chemotherapy in vivo. J Biomater Appl 2021; 36:592-604. [PMID: 33593129 DOI: 10.1177/0885328221989539] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The preferred cancer treatment is to achieve a high therapeutic effect as well as reduce side effects. In this study, we developed carrier-free nano drugs based on 5-fluorouracil (5FU) and cinnamaldehyde (CA) to meet the above goals. Two model drugs were spliced by acetal linkage and ester bond, which could self-assemble into nano drug particles (5FU-CA NPs) with a size of ∼170 nm. In vitro cell experiments showed 5FU-CA NPs were efficiently internalized by HepG2 cells. They then quickly exerted dual drug activities by the cleavage of acetal and ester bond, resulting in enhanced cell-killing efficacy and apoptosis. Synergistic mechanisms were achieved via the anti-metabolic effects mediated by 5FU-COOH and the oxidative damage induced by CA. In vivo anti-tumor evaluation further indicated that 5FU-CA NPs had higher tumor growth inhibition than 5FU-COOH/CA mixture (5FU-COOH + CA) and exhibited lower systemic toxicity under the same reducing dose of each drug. Overall, this is a successful synergistic anti-tumor attempt through rational self-assembly of drugs with different mechanisms and it can be extrapolated to other agents.
Collapse
Affiliation(s)
- Qin Fang
- School of Life Science, 12487Anhui University, Hefei, China
| | - Xiaoxiao Xu
- School of Life Science, 12487Anhui University, Hefei, China
| | - Longshun Yang
- School of Life Science, 12487Anhui University, Hefei, China
| | - Yanbing Xue
- School of Life Science, 12487Anhui University, Hefei, China
| | - Xu Cheng
- School of Life Science, 12487Anhui University, Hefei, China
| | - Xin Wang
- School of Life Science, 12487Anhui University, Hefei, China
| | - Rupei Tang
- School of Life Science, 12487Anhui University, Hefei, China
| |
Collapse
|
13
|
Optimized 5-Fluorouridine Prodrug for Co-Loading with Doxorubicin in Clinically Relevant Liposomes. Pharmaceutics 2021; 13:pharmaceutics13010107. [PMID: 33467652 PMCID: PMC7830726 DOI: 10.3390/pharmaceutics13010107] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2020] [Revised: 01/05/2021] [Accepted: 01/07/2021] [Indexed: 02/04/2023] Open
Abstract
Liposome-based drug delivery systems have allowed for better drug tolerability and longer circulation times but are often optimized for a single agent due to the inherent difficulty of co-encapsulating two drugs with differing chemical profiles. Here, we design and test a prodrug based on a ribosylated nucleoside form of 5-fluorouracil, 5-fluorouridine (5FUR), with the final purpose of co-encapsulation with doxorubicin (DOX) in liposomes. To improve the loading of 5FUR, we developed two 5FUR prodrugs that involved the conjugation of either one or three moieties of tryptophan (W) known respectively as, 5FUR−W and 5FUR−W3. 5FUR−W demonstrated greater chemical stability than 5FUR−W3 and allowed for improved loading with fewer possible byproducts from tryptophan hydrolysis. Varied drug ratios of 5FUR−W: DOX were encapsulated for in vivo testing in the highly aggressive 4T1 murine breast cancer model. A liposomal molar ratio of 2.5 5FUR−W: DOX achieved a 62.6% reduction in tumor size compared to the untreated control group and a 33% reduction compared to clinical doxorubicin liposomes in a proof-of-concept study to demonstrate the viability of the co-encapsulated liposomes. We believe that the new prodrug 5FUR−W demonstrates a prodrug design with clinical translatability by reducing the number of byproducts produced by the hydrolysis of tryptophan, while also allowing for loading flexibility.
Collapse
|
14
|
Zhang J, Zhou L, Zhang Y, He H, Yin T, Gou J, Wang Y, Tang X. Contrastive Studies of Cytarabine/Daunorubicin Dual-Loaded Liposomes Prepared by pH Gradient and Cu 2+ Gradient Method. AAPS PharmSciTech 2020; 21:325. [PMID: 33206247 DOI: 10.1208/s12249-020-01867-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2020] [Accepted: 10/28/2020] [Indexed: 12/16/2022] Open
Abstract
Conventional combination chemotherapy often leads to unsatisfactory clinical outcomes due to the different distribution characteristics in vivo and the superimposed systemic toxicity of the drug cocktail. Co-encapsulated nano preparations have been gradually developed in recent years. In this work, cytarabine (Ara-C)/daunorubicin (DNR) liposomes were prepared by the pH gradient (ADL-pH) and Cu2+ gradient (ADL-Cu) methods. Ara-C did not show significant release from either ADL-Cu or ADL-pH in vitro during 168 h, which related to its logPoct. Different drug-loading patterns showed different release characteristics of DNR due to the different existence forms, ADL-pH contains the citrate form, while in ADL-Cu, there is the Cu2+ complex. To evaluate the release behavior, daunorubicin liposome (DL) and daunorubicin-Cu2+ complex (DNR-Cu) were prepared. The addition of EDTA in the release medium significantly increased the release rate of DNR from DL-Cu, while lower pH accelerated DNR release from both DL-pH and DL-Cu. The PK confirmed that ADL-Cu and ADL-pH could prolong the drug circulation time, and ADL-Cu had a mean retention time 1.5 times that of ADL-pH. Furthermore, both liposomes allowed the two drugs to maintain a relatively constant plasma concentration ratio for a prolonged time. Cytotoxicity assays showed that Ara-C/DNR with a molar ratio of 5:1 and 3:1 exhibited an excellent synergistic effect, which was more obvious at 5:1. In vitro antitumor results revealed that ADL-Cu exhibited more cytotoxicity than ADL-pH. All factors tested in this work suggest the considerable potential of ADL-Cu and ADL-pH for anticancer treatment.
Collapse
|
15
|
Encapsulation of cucurbitacin B into lipid polymer hybrid nanocarriers induced apoptosis of MDAMB231 cells through PARP cleavage. Int J Pharm 2020; 586:119565. [DOI: 10.1016/j.ijpharm.2020.119565] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2020] [Revised: 06/17/2020] [Accepted: 06/19/2020] [Indexed: 12/24/2022]
|
16
|
Design principles of drug combinations for chemotherapy. J Control Release 2020; 323:36-46. [DOI: 10.1016/j.jconrel.2020.04.018] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2019] [Revised: 04/06/2020] [Accepted: 04/09/2020] [Indexed: 12/12/2022]
|
17
|
Schneible JD, Shi K, Young AT, Ramesh S, He N, Dowdey CE, Dubnansky JM, Lilova RL, Gao W, Santiso E, Daniele M, Menegatti S. Modified gaphene oxide (GO) particles in peptide hydrogels: a hybrid system enabling scheduled delivery of synergistic combinations of chemotherapeutics. J Mater Chem B 2020; 8:3852-3868. [PMID: 32219269 PMCID: PMC7945679 DOI: 10.1039/d0tb00064g] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
The scheduled delivery of synergistic drug combinations is increasingly recognized as highly effective against advanced solid tumors. Of particular interest are composite systems that release a sequence of drugs with defined kinetics and molar ratios to enhance therapeutic effect, while minimizing the dose to patients. In this work, we developed a homogeneous composite comprising modified graphene oxide (GO) nanoparticles embedded in a Max8 peptide hydrogel, which provides controlled kinetics and molar ratios of release of doxorubicin (DOX) and gemcitabine (GEM). First, modified GO nanoparticles (tGO) were designed to afford high DOX loading and sustained release (18.9% over 72 h and 31.4% over 4 weeks). Molecular dynamics simulations were utilized to model the mechanism of DOX loading as a function of surface modification. In parallel, a Max8 hydrogel was developed to release GEM with faster kinetics and achieve a 10-fold molar ratio to DOX. The selected DOX/tGO nanoparticles were suspended in a GEM/Max8 hydrogel matrix, and the resulting composite was tested against a triple negative breast cancer cell line, MDA-MB-231. Notably, the composite formulation afforded a combination index of 0.093 ± 0.001, indicating a much stronger synergism compared to the DOX-GEM combination co-administered in solution (CI = 0.396 ± 0.034).
Collapse
Affiliation(s)
- John D Schneible
- Department of Chemical and Biomolecular Engineering, North Carolina State University, 911 Partners Way, Raleigh, North Carolina, USA.
| | - Kaihang Shi
- Department of Chemical and Biomolecular Engineering, North Carolina State University, 911 Partners Way, Raleigh, North Carolina, USA.
| | - Ashlyn T Young
- Joint Department of Biomedical Engineering, North Carolina State University - University of North Carolina Chapel Hill, North Carolina, USA
| | - Srivatsan Ramesh
- Department of Chemical and Biomolecular Engineering, North Carolina State University, 911 Partners Way, Raleigh, North Carolina, USA.
| | - Nanfei He
- Department of Textile Engineering, Chemistry, and Science, 1020 Main Campus Drive, Raleigh, North Carolina, USA
| | - Clay E Dowdey
- Department of Chemical and Biomolecular Engineering, North Carolina State University, 911 Partners Way, Raleigh, North Carolina, USA.
| | - Jean Marie Dubnansky
- Department of Chemical and Biomolecular Engineering, North Carolina State University, 911 Partners Way, Raleigh, North Carolina, USA.
| | - Radina L Lilova
- Department of Chemical and Biomolecular Engineering, North Carolina State University, 911 Partners Way, Raleigh, North Carolina, USA.
| | - Wei Gao
- Department of Textile Engineering, Chemistry, and Science, 1020 Main Campus Drive, Raleigh, North Carolina, USA
| | - Erik Santiso
- Department of Chemical and Biomolecular Engineering, North Carolina State University, 911 Partners Way, Raleigh, North Carolina, USA.
| | - Michael Daniele
- Joint Department of Biomedical Engineering, North Carolina State University - University of North Carolina Chapel Hill, North Carolina, USA and Department of Electrical and Computer Engineering, North Carolina State University, 890 Oval Drive, Raleigh, North Carolina, USA.
| | - Stefano Menegatti
- Department of Chemical and Biomolecular Engineering, North Carolina State University, 911 Partners Way, Raleigh, North Carolina, USA.
| |
Collapse
|
18
|
Scheetz LM, Yu M, Li D, Castro MG, Moon JJ, Schwendeman A. Synthetic HDL Nanoparticles Delivering Docetaxel and CpG for Chemoimmunotherapy of Colon Adenocarcinoma. Int J Mol Sci 2020; 21:ijms21051777. [PMID: 32150841 PMCID: PMC7084365 DOI: 10.3390/ijms21051777] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2019] [Revised: 02/19/2020] [Accepted: 03/03/2020] [Indexed: 12/13/2022] Open
Abstract
Colon carcinomas comprise over two-thirds of all colorectal cancers with an overall 5-year survival rate of 64%, which rapidly decreases to 14% when the cancer becomes metastatic. Depending on the stage of colon carcinoma at diagnosis, patients can undergo surgery to attempt complete tumor resection or move directly to chemotherapy with one or a combination of drugs. As with most cancers, colon carcinomas do not always respond to chemotherapies, so targeted therapies and immunotherapies have been developed to aid chemotherapy. We report the development of a local combination therapy for colon carcinoma whereby chemo- and immunotherapeutic entities are delivered intratumorally to maximize efficacy and minimize off-target side effects. A hydrophobic chemotherapeutic agent, docetaxel (DTX), and cholesterol-modified Toll-like receptor 9 (TLR9) agonist CpG (cho-CpG) oligonucleotide are co-loaded in synthetic HDL (sHDL) nanodiscs. In vivo survival analysis of MC-38 tumor-bearing mice treated intratumorally with DTX-sHDL/CpG (median survival; MS = 43 days) showed significant improvement in overall survival compared to mice treated with single agents, free DTX (MS = 23 days, p < 0.0001) or DTX-sHDL (MS = 28 days, p < 0.0001). Two of seven mice treated with DTX-sHDL/CpG experienced complete tumor regression. None of the mice experienced any systemic toxicity as indicated by body weight maintenance and normal serum enzyme and protein levels. In summary, we have demonstrated that chemo- and immunotherapies can be co-loaded into sHDLs, delivered locally to the tumor, and can be used to improve survival outcomes significantly compared to chemotherapy alone.
Collapse
Affiliation(s)
- Lindsay M. Scheetz
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA; (L.M.S.); (M.Y.); (D.L.)
- Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA
| | - Minzhi Yu
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA; (L.M.S.); (M.Y.); (D.L.)
- Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA
| | - Dan Li
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA; (L.M.S.); (M.Y.); (D.L.)
- Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA
| | - María G. Castro
- Department of Neurosurgery, University of Michigan School of Medicine, Ann Arbor, MI 48109, USA;
- Department of Cell and Developmental Biology, University of Michigan School of Medicine, Ann Arbor, MI 48109, USA
| | - James J. Moon
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA; (L.M.S.); (M.Y.); (D.L.)
- Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA
- Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA
- Correspondence: (J.J.M.); (A.S.); Tel.: +734-763-4056 (A.S.)
| | - Anna Schwendeman
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA; (L.M.S.); (M.Y.); (D.L.)
- Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA
- Correspondence: (J.J.M.); (A.S.); Tel.: +734-763-4056 (A.S.)
| |
Collapse
|
19
|
Gonçalves M, Mignani S, Rodrigues J, Tomás H. A glance over doxorubicin based-nanotherapeutics: From proof-of-concept studies to solutions in the market. J Control Release 2020; 317:347-374. [PMID: 31751636 DOI: 10.1016/j.jconrel.2019.11.016] [Citation(s) in RCA: 52] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2019] [Revised: 11/12/2019] [Accepted: 11/13/2019] [Indexed: 02/07/2023]
Abstract
Cancer is one of the leading causes of death worldwide and, as such, efforts are being done to find new chemotherapeutic drugs or, alternatively, novel approaches for the delivery of old ones. In this scope, when used as vehicles for drugs, nanomaterials may potentially maximize the efficacy of the treatment and reduce its side effects, for example by a change in drug's pharmacokinetics, cell targeting and/or specific stimuli-responsiveness. This is the case of doxorubicin (DOX) that presents a broad spectrum of activity and is one of the most widely used chemotherapeutic drugs as first-line treatment. Indeed, DOX is a very interesting example of a drug for which several nanosized delivery systems have been developed over the years. While it is true that some of these systems are already in the market, it is also true that research on this subject remains very active and that there is a continuing search for new solutions. In this sense, this review takes the example of doxorubicin, not so much with the focus on the drug itself, but rather as a case study around which very diverse and imaginative nanotechnology approaches have emerged.
Collapse
Affiliation(s)
- Mara Gonçalves
- CQM-Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus Universitário da Penteada, 9020-105 Funchal, Portugal
| | - Serge Mignani
- CQM-Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus Universitário da Penteada, 9020-105 Funchal, Portugal; Université Paris Descartes, PRES Sorbonne Paris Cité, CNRS UMR 860, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologique, 45, rue des Saints Peres, 75006 Paris, France
| | - João Rodrigues
- CQM-Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus Universitário da Penteada, 9020-105 Funchal, Portugal; School of Materials Science and Engineering, Center for Nano Energy Materials, Northwestern Polytechnical University, Xi'an 710072, China
| | - Helena Tomás
- CQM-Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus Universitário da Penteada, 9020-105 Funchal, Portugal.
| |
Collapse
|
20
|
Gonçalves M, Mignani S, Rodrigues J, Tomás H. A glance over doxorubicin based-nanotherapeutics: From proof-of-concept studies to solutions in the market. J Control Release 2020. [DOI: https://doi.org/10.1016/j.jconrel.2019.11.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
21
|
El-Hammadi MM, Arias JL. An update on liposomes in drug delivery: a patent review (2014-2018). Expert Opin Ther Pat 2019; 29:891-907. [DOI: 10.1080/13543776.2019.1679767] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- Mazen M. El-Hammadi
- Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Seville, Seville, Spain
| | - José L. Arias
- Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, Granada, Spain
- Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of Granada, Granada, Spain
- Biosanitary Research Institute of Granada (ibs.GRANADA), Andalusian Health Service (SAS), University of Granada, Granada, Spain
| |
Collapse
|
22
|
Schneible JD, Singhal A, Lilova RL, Hall CK, Grafmüller A, Menegatti S. Tailoring the Chemical Modification of Chitosan Hydrogels to Fine-Tune the Release of a Synergistic Combination of Chemotherapeutics. Biomacromolecules 2019; 20:3126-3141. [PMID: 31310515 DOI: 10.1021/acs.biomac.9b00707] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Combination chemotherapy with a defined ratio and sequence of drug release is a clinically established and effective route to treat advanced solid tumors. In this context, a growing body of literature demonstrates the potential of hydrogels constructed with chemically modified polysaccharides as depots for controlled release of chemotherapeutics. Identifying the appropriate modification in terms of physicochemical properties of the functional group and its degree of substitution (χ) to achieve the desired release profile for multiple drugs is, however, a complex multivariate problem. To address this issue, we have developed a computational toolbox that models the migration of a drug pair through a hydrated network of polysaccharide chains modified with hydrophobic moieties. In this study, we chose doxorubicin (DOX) and Gemcitabine (GEM) as model drugs, as their synergistic effect against breast cancer has been thoroughly investigated, and chitosan as the model polymer. Our model describes how the modification of chitosan chains with acetyl, butanoyl, and heptanoyl moieties at different values χ governs both the structure of the hydrogel network and drug migration through it. Our experimental data confirm the in silico predictions for both single- and dual-drug release and, most notably, the counterintuitive inversion of release vs χ that occurs when switching from a single- to a dual-drug system. Consensus between predicted and experimental data indicates that acetyl modifications (χ = 32-42%) and butanoyl modifications (χ = 19-24%) provide synergistic GEM/DOX release molar ratios (i.e., 5-10). Collectively, these results demonstrate the potential of this model in guiding the design of chemotherapeutic hydrogels to combat cancer.
Collapse
Affiliation(s)
- John D Schneible
- Department of Chemical and Biomolecular Engineering , North Carolina State University , Raleigh , North Carolina 27695 , United States
| | - Ankush Singhal
- Department of Theory and Biosystems , Max Planck Institute for Colloids and Interfaces , Potsdam 14476 , Germany
| | - Radina L Lilova
- Department of Chemical and Biomolecular Engineering , North Carolina State University , Raleigh , North Carolina 27695 , United States
| | - Carol K Hall
- Department of Chemical and Biomolecular Engineering , North Carolina State University , Raleigh , North Carolina 27695 , United States
| | - Andrea Grafmüller
- Department of Theory and Biosystems , Max Planck Institute for Colloids and Interfaces , Potsdam 14476 , Germany
| | - Stefano Menegatti
- Department of Chemical and Biomolecular Engineering , North Carolina State University , Raleigh , North Carolina 27695 , United States
| |
Collapse
|
23
|
Depalo N, Fanizza E, Vischio F, Denora N, Laquintana V, Cutrignelli A, Striccoli M, Giannelli G, Agostiano A, Curri ML, Scavo MP. Imaging modification of colon carcinoma cells exposed to lipid based nanovectors for drug delivery: a scanning electron microscopy investigation. RSC Adv 2019; 9:21810-21825. [PMID: 35518842 PMCID: PMC9066453 DOI: 10.1039/c9ra02381j] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2019] [Accepted: 07/10/2019] [Indexed: 11/21/2022] Open
Abstract
The adsorption at cell surfaces and cell internalization of two drug delivery lipid based nanovectors has been investigated by means of Field Emission Scanning Electron Microscopy (FE-SEM) operating at low beam voltage on two different colon carcinoma cell lines, CaCo-2 and CoLo-205, that were compared with the M14 melanoma cell line, as a reference. The cells were incubated with the investigated multifunctional nanovectors, based on liposomes and magnetic micelles loaded with 5-fluorouracil, as a chemotherapeutic agent, and a FE-SEM systematic investigation was performed, enabling a detailed imaging of any morphological changes of the drug exposed cells as a function of time. The results of the FE-SEM investigation were validated by MTS assay and immunofluorescence staining of the Ki-67 protein performed on the investigated cell lines at different times. The two nanoformulations resulted in a comparable effect on CaCo-2 and M14 cell lines, while for CoLo 205 cells, the liposomes provided an cytotoxic activity higher than that observed in the case of the micelles. The study highlighted the high potential of FE-SEM as a valuable complementary technique for imaging and monitoring in time the drug effects on the selected cells exposed to the two different nanoformulations.
Collapse
Affiliation(s)
- Nicoletta Depalo
- Institute for Physical-Chemical Processes (IPCF)-CNR SS Bari Via Orabona 4 70125 Bari Italy
| | - Elisabetta Fanizza
- Institute for Physical-Chemical Processes (IPCF)-CNR SS Bari Via Orabona 4 70125 Bari Italy
- Università degli Studi di Bari Aldo Moro, Dipartimento di Chimica Via Orabona 4 70125 Bari Italy
| | - Fabio Vischio
- Università degli Studi di Bari Aldo Moro, Dipartimento di Chimica Via Orabona 4 70125 Bari Italy
| | - Nunzio Denora
- Institute for Physical-Chemical Processes (IPCF)-CNR SS Bari Via Orabona 4 70125 Bari Italy
- Università degli Studi di Bari Aldo Moro, Dipartimento di Farmacia, Scienze del Farmaco Via Orabona 4 70125 Bari Italy
| | - Valentino Laquintana
- Università degli Studi di Bari Aldo Moro, Dipartimento di Farmacia, Scienze del Farmaco Via Orabona 4 70125 Bari Italy
| | - Annalisa Cutrignelli
- Università degli Studi di Bari Aldo Moro, Dipartimento di Farmacia, Scienze del Farmaco Via Orabona 4 70125 Bari Italy
| | - Marinella Striccoli
- Institute for Physical-Chemical Processes (IPCF)-CNR SS Bari Via Orabona 4 70125 Bari Italy
| | - Gianluigi Giannelli
- Personalized Medicine Laboratory, National Institute of Gastroenterology - Research Hospital "S. De Bellis" Via Turi 27, Castellana Grotte Bari Italy
| | - Angela Agostiano
- Institute for Physical-Chemical Processes (IPCF)-CNR SS Bari Via Orabona 4 70125 Bari Italy
- Università degli Studi di Bari Aldo Moro, Dipartimento di Chimica Via Orabona 4 70125 Bari Italy
| | - Maria Lucia Curri
- Institute for Physical-Chemical Processes (IPCF)-CNR SS Bari Via Orabona 4 70125 Bari Italy
- Università degli Studi di Bari Aldo Moro, Dipartimento di Chimica Via Orabona 4 70125 Bari Italy
| | - Maria Principia Scavo
- Personalized Medicine Laboratory, National Institute of Gastroenterology - Research Hospital "S. De Bellis" Via Turi 27, Castellana Grotte Bari Italy
| |
Collapse
|
24
|
Immunological consequences of chemotherapy: Single drugs, combination therapies and nanoparticle-based treatments. J Control Release 2019; 305:130-154. [DOI: 10.1016/j.jconrel.2019.04.020] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2019] [Revised: 04/09/2019] [Accepted: 04/14/2019] [Indexed: 02/07/2023]
|
25
|
Pusuluri A, Krishnan V, Wu D, Shields CW, Wang LW, Mitragotri S. Role of synergy and immunostimulation in design of chemotherapy combinations: An analysis of doxorubicin and camptothecin. Bioeng Transl Med 2019; 4:e10129. [PMID: 31249879 PMCID: PMC6584462 DOI: 10.1002/btm2.10129] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2019] [Revised: 03/09/2019] [Accepted: 03/26/2019] [Indexed: 01/03/2023] Open
Abstract
Combination chemotherapy is often employed to improve therapeutic efficacies of drugs. However, traditional combination regimens often utilize drugs at or near-their maximum tolerated doses (MTDs), elevating the risk of dose-related toxicity and impeding their clinical success. Further, high doses of adjuvant or neoadjuvant chemotherapies can cause myeloablation, which compromises the immune response and hinders the efficacy of chemotherapy as well as accompanying treatments such as immunotherapy. Clinical outcomes can be improved if chemotherapy combinations are designed to reduce the overall doses without compromising their therapeutic efficacy. To this end, we investigated a combination of camptothecin (CPT) with doxorubicin (DOX) as a low-dose treatment option for breast cancer. DOX-CPT combinations were synergistic in several breast cancer cell lines in vitro and one particular ratio displayed extremely high synergy on human triple negative breast cancer cells (MDA-MB-231). This combination led to excellent long-term survival of mice bearing MDA-MB-231 tumors at doses roughly five-fold lower than the reported MTD values of its constituent drugs. Impact of low dose DOX-CPT treatment on local tumor immune environment was assessed in immunocompetent mice bearing breast cancer (4T1) tumors. The combination was not only superior in inhibiting the disease progression compared to individual drugs, but it also generated a more favorable antitumor immunogenic response. Engineering DOX and CPT ratios to manifest synergy enables treatment at doses much lower than their MTDs, which could ultimately facilitate their translation into the clinic as a promising combination for breast cancer treatment.
Collapse
Affiliation(s)
- Anusha Pusuluri
- John A. Paulson School of Engineering and Applied Sciences, Harvard UniversityCambridgeMA 02138
- Wyss Institute of Biologically Inspired Engineering, Harvard UniversityBostonMA 02115
- Department of Chemical EngineeringUniversity of CaliforniaSanta BarbaraCA 93106
| | - Vinu Krishnan
- John A. Paulson School of Engineering and Applied Sciences, Harvard UniversityCambridgeMA 02138
- Wyss Institute of Biologically Inspired Engineering, Harvard UniversityBostonMA 02115
| | - Debra Wu
- John A. Paulson School of Engineering and Applied Sciences, Harvard UniversityCambridgeMA 02138
- Wyss Institute of Biologically Inspired Engineering, Harvard UniversityBostonMA 02115
| | - C. Wyatt Shields
- John A. Paulson School of Engineering and Applied Sciences, Harvard UniversityCambridgeMA 02138
- Wyss Institute of Biologically Inspired Engineering, Harvard UniversityBostonMA 02115
| | - Li W. Wang
- John A. Paulson School of Engineering and Applied Sciences, Harvard UniversityCambridgeMA 02138
- Wyss Institute of Biologically Inspired Engineering, Harvard UniversityBostonMA 02115
- Harvard–MIT Health Sciences and Technology ProgramInstitute for Medical Engineering and Science, Massachusetts Institute of TechnologyCambridgeMA 02139
| | - Samir Mitragotri
- John A. Paulson School of Engineering and Applied Sciences, Harvard UniversityCambridgeMA 02138
- Wyss Institute of Biologically Inspired Engineering, Harvard UniversityBostonMA 02115
| |
Collapse
|
26
|
Li XJ, Li WT, Li ZHR, Zhang LP, Gai CC, Zhang WF, Ding DJ. Iron-Chelated Polydopamine Decorated Doxorubicin-Loaded Nanodevices for Reactive Oxygen Species Enhanced Cancer Combination Therapy. Front Pharmacol 2019; 10:75. [PMID: 30787876 PMCID: PMC6372743 DOI: 10.3389/fphar.2019.00075] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2018] [Accepted: 01/21/2019] [Indexed: 01/07/2023] Open
Abstract
Combination therapy which enhances efficacy and reduces toxicity, has been increasingly applied as a promising strategy for cancer therapy. Here, a reactive oxygen species (ROS) that enhanced combination chemotherapy nanodevices was fabricated based on the Fe-chelated polydopamine (PDA) nanoparticles (NPs). The structure was characterized by dynamic light scattering-autosizer, transmission electron microscopy, energy dispersive spectroscopy, and Fourier-transform infrared (FT-IR) spectrophotometer. The in vitro drug release profile triggered by low intracellular pH indicated that the system demonstrated controlled therapeutic activity. In vitro cell uptake studies showed that doxorubicin (DOX)-loaded Fe-PDA/ folic acid (FA)- polyethylene glycol (DOX@Fe-PDA/FA-PEG) had a strong uptake capacity and can be rapidly internalized by MCF-7 cells. The in vitro experiments demonstrated that DOX@Fe-PDA/FA-PEG triggered the intracellular ROS overproduction, thereby enhancing its therapeutic effect on breast cancer. In summary, this experiment demonstrated the novel DOX-loaded composite NPs used as a potential targeted nanocarrier for breast cancer treatment, which could be a promising therapeutic strategy against breast cancer.
Collapse
Affiliation(s)
- Xu-Jing Li
- Department of Pathology, Weifang Medical University, Weifang, China
| | - Wen-Tong Li
- Department of Pathology, Weifang Medical University, Weifang, China.,Collaborative Innovation Center for Target Drug Delivery System, Weifang Medical University, Weifang, China
| | - Zi-Hao-Ran Li
- Department of Pathology, Weifang Medical University, Weifang, China
| | - Li-Ping Zhang
- College of Pharmacy, Weifang Medical University, Weifang, China
| | - Cheng-Cheng Gai
- Department of Pathology, Weifang Medical University, Weifang, China
| | - Wei-Fen Zhang
- Collaborative Innovation Center for Target Drug Delivery System, Weifang Medical University, Weifang, China.,College of Pharmacy, Weifang Medical University, Weifang, China
| | - De-Jun Ding
- Collaborative Innovation Center for Target Drug Delivery System, Weifang Medical University, Weifang, China.,College of Pharmacy, Weifang Medical University, Weifang, China
| |
Collapse
|
27
|
Pusuluri A, Krishnan V, Lensch V, Sarode A, Bunyan E, Vogus DR, Menegatti S, Soh HT, Mitragotri S. Treating Tumors at Low Drug Doses Using an Aptamer-Peptide Synergistic Drug Conjugate. Angew Chem Int Ed Engl 2018; 58:1437-1441. [PMID: 30537284 DOI: 10.1002/anie.201812650] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2018] [Indexed: 11/06/2022]
Abstract
Combination chemotherapy must strike a difficult balance between safety and efficacy. Current regimens suffer from poor therapeutic impact because drugs are given at their maximum tolerated dose (MTD), which compounds the toxicity risk and exposes tumors to non-optimal drug ratios. A modular framework has been developed that selectively delivers drug combinations at synergistic ratios via tumor-targeting aptamers for effective low-dose treatment. A nucleolin-recognizing aptamer was coupled to peptide scaffolds laden with precise ratios of doxorubicin (DOX) and camptothecin (CPT). This construct had an extremely low IC50 (31.9 nm) against MDA-MB-231 breast cancer cells in vitro, and exhibited in vivo efficacy at micro-dose injections (500 and 350 μg kg-1 dose-1 of DOX and CPT, respectively) that are 20-30-fold lower than their previously-reported MTDs. This approach represents a generalizable strategy for the safe and consistent delivery of combination drugs in oncology.
Collapse
Affiliation(s)
- Anusha Pusuluri
- John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA.,Wyss Institute of Biologically Inspired Engineering, Harvard University, Harvard University, Boston, MA, 02115, USA.,Department of Chemical Engineering, University of California, Santa Barbara, CA, 93106, USA
| | - Vinu Krishnan
- John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA.,Wyss Institute of Biologically Inspired Engineering, Harvard University, Harvard University, Boston, MA, 02115, USA
| | - Valerie Lensch
- Department of Chemical Engineering, University of California, Santa Barbara, CA, 93106, USA
| | - Apoorva Sarode
- John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA.,Wyss Institute of Biologically Inspired Engineering, Harvard University, Harvard University, Boston, MA, 02115, USA
| | - Elaine Bunyan
- Department of Chemical Engineering, University of California, Santa Barbara, CA, 93106, USA
| | - Douglas R Vogus
- John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA.,Wyss Institute of Biologically Inspired Engineering, Harvard University, Harvard University, Boston, MA, 02115, USA
| | - Stefano Menegatti
- Department of Chemical & Biomolecular Engineering, North Carolina State University, Raleigh, NC, 27606, USA
| | - H Tom Soh
- Department of Electrical Engineering and Department of Radiology, Stanford University, Palo Alto, CA, 94305, USA
| | - Samir Mitragotri
- John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA.,Wyss Institute of Biologically Inspired Engineering, Harvard University, Harvard University, Boston, MA, 02115, USA
| |
Collapse
|
28
|
Pusuluri A, Krishnan V, Lensch V, Sarode A, Bunyan E, Vogus DR, Menegatti S, Soh HT, Mitragotri S. Treating Tumors at Low Drug Doses Using an Aptamer–Peptide Synergistic Drug Conjugate. Angew Chem Int Ed Engl 2018. [DOI: 10.1002/ange.201812650] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Anusha Pusuluri
- John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge MA 02138 USA
- Wyss Institute of Biologically Inspired Engineering, Harvard University Harvard University Boston MA 02115 USA
- Department of Chemical Engineering University of California Santa Barbara CA 93106 USA
| | - Vinu Krishnan
- John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge MA 02138 USA
- Wyss Institute of Biologically Inspired Engineering, Harvard University Harvard University Boston MA 02115 USA
| | - Valerie Lensch
- Department of Chemical Engineering University of California Santa Barbara CA 93106 USA
| | - Apoorva Sarode
- John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge MA 02138 USA
- Wyss Institute of Biologically Inspired Engineering, Harvard University Harvard University Boston MA 02115 USA
| | - Elaine Bunyan
- Department of Chemical Engineering University of California Santa Barbara CA 93106 USA
| | - Douglas R. Vogus
- John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge MA 02138 USA
- Wyss Institute of Biologically Inspired Engineering, Harvard University Harvard University Boston MA 02115 USA
| | - Stefano Menegatti
- Department of Chemical & Biomolecular Engineering North Carolina State University Raleigh NC 27606 USA
| | - H. Tom Soh
- Department of Electrical Engineering and Department of Radiology Stanford University Palo Alto CA 94305 USA
| | - Samir Mitragotri
- John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge MA 02138 USA
- Wyss Institute of Biologically Inspired Engineering, Harvard University Harvard University Boston MA 02115 USA
| |
Collapse
|
29
|
Ahmed KS, Hussein SA, Ali AH, Korma SA, Lipeng Q, Jinghua C. Liposome: composition, characterisation, preparation, and recent innovation in clinical applications. J Drug Target 2018; 27:742-761. [PMID: 30239255 DOI: 10.1080/1061186x.2018.1527337] [Citation(s) in RCA: 129] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
In the last decades, pharmaceutical interested researches aimed to develop novel and innovative drug delivery techniques in the medical and pharmaceutical fields. Recently, phospholipid vesicles (Liposomes) are the most known versatile assemblies in the drug delivery systems. The discovery of liposomes arises from self-forming enclosed phospholipid bilayer upon coming in contact with the aqueous solution. Liposomes are uni or multilamellar vesicles consisting of phospholipids produced naturally or synthetically, which are readily non-toxic, biodegradable, and are readily produced on a large scale. Various phospholipids, for instance, soybean, egg yolk, synthetic, and hydrogenated phosphatidylcholine consider the most popular types used in different kinds of formulations. This review summarises liposomes composition, characterisation, methods of preparation, and their applications in different medical fields including cancer therapy, vaccine, ocular delivery, wound healing, and some dermatological applications.
Collapse
Affiliation(s)
- Kamel S Ahmed
- a Department of Pharmaceutics , School of Pharmaceutical Sciences, Jiangnan University , Wuxi , PR China.,b Department of Pharmaceutics , Faculty of Pharmacy, Minia University , Minia , Egypt
| | - Saied A Hussein
- c Department of Biomedical Engineering , College of Life Science and Technology, Huazhong University of Science and Technology , Wuhan , PR China
| | - Abdelmoneim H Ali
- d State Key Laboratory of Food Science and Technology, Synergetic Innovation Center of Food Safety and Nutrition, School of Food Science and Technology, Jiangnan University , Wuxi , PR China
| | - Sameh A Korma
- d State Key Laboratory of Food Science and Technology, Synergetic Innovation Center of Food Safety and Nutrition, School of Food Science and Technology, Jiangnan University , Wuxi , PR China
| | - Qiu Lipeng
- a Department of Pharmaceutics , School of Pharmaceutical Sciences, Jiangnan University , Wuxi , PR China
| | - Chen Jinghua
- a Department of Pharmaceutics , School of Pharmaceutical Sciences, Jiangnan University , Wuxi , PR China
| |
Collapse
|
30
|
Electroneutral polymersomes for combined cancer chemotherapy. Acta Biomater 2018; 80:327-340. [PMID: 30201433 DOI: 10.1016/j.actbio.2018.09.005] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Revised: 09/03/2018] [Accepted: 09/06/2018] [Indexed: 02/06/2023]
Abstract
Combination cancer chemotherapy provides an important treatment tool, both as an adjuvant and neoadjuvant treatment, this shift in focus from mono to combination therapies has led to increased interest in drug delivery systems (DDS). DDSs, such as polymersomes, are capable of encapsulating large amounts of multiple drugs with both hydrophilic and hydrophobic properties simultaneously, as well as offering a mechanism to combat multi drug resistant cancers and poor patient tolerance of the cytotoxic compounds utilised. In this article, we report the formulation and evaluation of a novel electroneutral polymersome capable of high encapsulation efficacies for multiple drugs (Doxorubicin, 5-Fluorouracil and leucovorin). The in-vivo biodistribution of the polymersome were established and they were found to accumulate largely in tumour tissue. Polymersome encapsulating the three chemotherapeutic drugs were assessed both in-vitro (BxPC-3 cell line) and in-vivo (following intratumoral and intravenous administration) and compared with the same concentration of the three drugs in solution. We report better efficacy and higher maximum tolerated dose for our combination drug loaded polymersomes in all experiments. Furthermore, intratumorally injected combination drug loaded polymersomes exhibited a 62% reduction in tumour volume after 13 days when compared with the free combination solutions. A smaller differential of 13% was observed for when treatment was administered intravenously however, importantly less cardiotoxicity was displayed from the polymersomal DDS. In this study, expression of a number of survival-relevant genes in tumours treated with the free chemotherapy combination was compared with expression of those genes in tumours treated with the polymersomes harbouring those drugs and the significance of findings is discussed. STATEMENT OF SIGNIFICANCE: The shift in focus from mono to combination chemotherapies has led to an increased interest in the role of drug delivery systems (DDS). Liposomes, although commercialized for mono therapy, have lower loading capacities and stability than their polymeric counterpart, polymersomes. Polymersomes are growing in prevalence as their advantageous properties are better understood and exploited. Here we present a novel polymersome for the encapsulation of three anticancer compounds. This is the first time this particular polymersome has been used to encapsulate these three compounds with both an in-vitro and in-vivo evaluation carried out. This work will be of interest to those in the field of combination therapy, drug delivery, drug toxicity, multidrug resistance, liposomes, DDS and polymersomes.
Collapse
|
31
|
Villarreal-Gómez LJ, Serrano-Medina A, José Torres-Martínez E, Lizeth Perez-González G, Manuel Cornejo-Bravo J. Polymeric advanced delivery systems for antineoplasic drugs: doxorubicin and 5-fluorouracil. E-POLYMERS 2018. [DOI: 10.1515/epoly-2017-0202] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
AbstractConventional pharmaceuticals generally display the inability to transport active ingredients directly to specific regions of the body, amongst some of their main limitations. The distribution of the drugs in the circulatory system may lead to undesired toxicity, and therefore, adverse reactions. To address this situation, a selective transport of drugs is required, that is, releasing drugs specifically to the site of action in appropriate concentrations and in the right time. To achieve this goal, it is necessary to develop delivery systems that respond to several features, such as low toxicity, optimum properties for the transport and release of the drug, as well as a long half-life in the body. This feature paper critically provides an overview of different strategies of controlled drug release for two model antineoplasic drugs, i.e. doxorubicin (DOX) and 5-fluorouracil (5-FU). Any of the presented strategies for drug release possess advantages and disadvantages, and the selection of the strategy used will depend on the targeted tissue and nature of the drug.
Collapse
Affiliation(s)
- Luis Jesús Villarreal-Gómez
- Universidad Autónoma de Baja California, Calzada Universidad 14418, Parque Industrial Internacional, Tijuana, Baja California C.P. 22390, México
- Escuela de Ciencias de la Ingeniería y Tecnología, Universidad Autónoma de Baja California, Unidad Valle de las Palmas, Tijuana, Baja California, México
- Facultad de Ciencias Químicas e Ingeniería, Universidad Autónoma de Baja California, Unidad Otay, Tijuana, Baja California, México
| | - Aracely Serrano-Medina
- Universidad Autónoma de Baja California, Calzada Universidad 14418, Parque Industrial Internacional, Tijuana, Baja California C.P. 22390, México
- Facultad de Medicina y Psicología, Universidad Autónoma de Baja California, Unidad Otay, Tijuana, Baja California, México
| | - Erick José Torres-Martínez
- Universidad Autónoma de Baja California, Calzada Universidad 14418, Parque Industrial Internacional, Tijuana, Baja California C.P. 22390, México
- Escuela de Ciencias de la Ingeniería y Tecnología, Universidad Autónoma de Baja California, Unidad Valle de las Palmas, Tijuana, Baja California, México
| | - Graciela Lizeth Perez-González
- Universidad Autónoma de Baja California, Calzada Universidad 14418, Parque Industrial Internacional, Tijuana, Baja California C.P. 22390, México
- Escuela de Ciencias de la Ingeniería y Tecnología, Universidad Autónoma de Baja California, Unidad Valle de las Palmas, Tijuana, Baja California, México
- Facultad de Ciencias Químicas e Ingeniería, Universidad Autónoma de Baja California, Unidad Otay, Tijuana, Baja California, México
| | - José Manuel Cornejo-Bravo
- Universidad Autónoma de Baja California, Calzada Universidad 14418, Parque Industrial Internacional, Tijuana, Baja California C.P. 22390, México
- Facultad de Ciencias Químicas e Ingeniería, Universidad Autónoma de Baja California, Unidad Otay, Tijuana, Baja California, México
| |
Collapse
|
32
|
Qin SY, Cheng YJ, Lei Q, Zhang AQ, Zhang XZ. Combinational strategy for high-performance cancer chemotherapy. Biomaterials 2018; 171:178-197. [DOI: 10.1016/j.biomaterials.2018.04.027] [Citation(s) in RCA: 128] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2017] [Revised: 04/10/2018] [Accepted: 04/14/2018] [Indexed: 12/21/2022]
|
33
|
Hierarchical drug release of pH-sensitive liposomes encapsulating aqueous two phase system. Eur J Pharm Biopharm 2018; 127:177-182. [DOI: 10.1016/j.ejpb.2018.02.021] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2017] [Revised: 12/26/2017] [Accepted: 02/16/2018] [Indexed: 12/20/2022]
|
34
|
Yu L, Dong A, Guo R, Yang M, Deng L, Zhang J. DOX/ICG Coencapsulated Liposome-Coated Thermosensitive Nanogels for NIR-Triggered Simultaneous Drug Release and Photothermal Effect. ACS Biomater Sci Eng 2018; 4:2424-2434. [DOI: 10.1021/acsbiomaterials.8b00379] [Citation(s) in RCA: 65] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Lixia Yu
- Department of Polymer Science and Engineering, Key Laboratory of Systems Bioengineering (Ministry of Education), School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China
| | - Anjie Dong
- Department of Polymer Science and Engineering, Key Laboratory of Systems Bioengineering (Ministry of Education), School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China
- Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin 300072, China
| | - Ruiwei Guo
- Department of Polymer Science and Engineering, Key Laboratory of Systems Bioengineering (Ministry of Education), School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China
| | - Muyang Yang
- Department of Polymer Science and Engineering, Key Laboratory of Systems Bioengineering (Ministry of Education), School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China
| | - Liandong Deng
- Department of Polymer Science and Engineering, Key Laboratory of Systems Bioengineering (Ministry of Education), School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China
| | - Jianhua Zhang
- Department of Polymer Science and Engineering, Key Laboratory of Systems Bioengineering (Ministry of Education), School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China
- Tianjin Key Laboratory of Membrane Science and Desalination Technology, Tianjin University, Tianjin 300072, China
| |
Collapse
|
35
|
Dual functionality nanobioconjugates: a new tool for intracellular bacterial targeting in cancer cells? Ther Deliv 2018; 9:317-320. [PMID: 29681234 DOI: 10.4155/tde-2018-0010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
36
|
Jarvis M, Arnold M, Ott J, Krishnan V, Pant K, Prabhakarpandian B, Mitragotri S. Detachment of ligands from nanoparticle surface under flow and endothelial cell contact: Assessment using microfluidic devices. Bioeng Transl Med 2018; 3:148-155. [PMID: 30065969 PMCID: PMC6063868 DOI: 10.1002/btm2.10089] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2017] [Revised: 03/16/2018] [Accepted: 03/21/2018] [Indexed: 01/09/2023] Open
Abstract
Surface modification of nanoparticles is a well‐established methodology to alter their properties to enhance circulation half‐life. While literature studies using conventional, in vitro characterization are routinely used to evaluate the biocompatibility of such modifications, relatively little attention has been paid to assess the stability of such surface modifications in physiologically relevant conditions. Here, microfluidic devices were used to study the effect of factors that adversely impact surface modifications including vascular flow and endothelial cell interactions. Camptothecin nanoparticles coated with polyethylene glycol (PEG) and/or folic acid were analyzed using linear channels and microvascular networks. Detachment of PEG was observed in cell‐free conditions and was attributed to interplay between the flow and method of PEG attachment. The flow and cells also impacted the surface charge of nanoparticles. Presence of endothelial cells further increased PEG shedding. The results demonstrate that endothelial cell contact, and vascular flow parameters modify surface ligands on nanoparticle surfaces.
Collapse
Affiliation(s)
- Maria Jarvis
- Biomolecular Sciences and Engineering Program University of California Santa Barbara CA 93106
| | - Michael Arnold
- Dept. of Molecular, Cellular and Developmental Biology University of California Santa Barbara CA 93106
| | - Jenna Ott
- Dept. of Chemical Engineering University of California Santa Barbara CA 93106
| | - Vinu Krishnan
- Dept. of Chemical Engineering University of California Santa Barbara CA 93106
| | - Kapil Pant
- Biomedical Technology, CFD Research Corporation Huntsville AL 35806
| | | | - Samir Mitragotri
- Dept. of Chemical Engineering University of California Santa Barbara CA 93106.,John A. Paulson School of Engineering and Applied Sciences Wyss Institute, Harvard University Cambridge MA 02138
| |
Collapse
|
37
|
Jiang C, Zhao Y, Yang Y, He J, Zhang W, Liu J. Evaluation of the Combined Effect of Recombinant High-Density Lipoprotein Carrier and the Encapsulated Lovastatin in RAW264.7 Macrophage Cells Based on the Median-Effect Principle. Mol Pharm 2018; 15:1017-1027. [DOI: 10.1021/acs.molpharmaceut.7b00923] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Cuiping Jiang
- Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210008, PR China
| | - Yi Zhao
- Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210008, PR China
| | - Yun Yang
- Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210008, PR China
| | - Jianhua He
- Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210008, PR China
| | - Wenli Zhang
- Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210008, PR China
| | - Jianping Liu
- Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210008, PR China
| |
Collapse
|
38
|
Zhang X, Zong W, Cheng W, Han X. Codelivery of doxorubicin and sodium tanshinone IIA sulfonate using multicompartmentalized vesosomes to enhance synergism and prevent doxorubicin-induced cardiomyocyte apoptosis. J Mater Chem B 2018; 6:5243-5247. [DOI: 10.1039/c8tb01136b] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Doxorubicin, one of the most effective antitumor drugs, causes serious adverse cardiac effects.
Collapse
Affiliation(s)
- Xunan Zhang
- State Key Laboratory of Urban Water Resource and Environment
- School of Chemical Engineering and Technology
- Harbin Institute of Technology
- China
| | - Wei Zong
- State Key Laboratory of Urban Water Resource and Environment
- School of Chemical Engineering and Technology
- Harbin Institute of Technology
- China
| | - Wenlong Cheng
- Department of Chemical Engineering
- Monash University
- Australia
| | - Xiaojun Han
- State Key Laboratory of Urban Water Resource and Environment
- School of Chemical Engineering and Technology
- Harbin Institute of Technology
- China
| |
Collapse
|
39
|
Fromen CA, Kelley WJ, Fish MB, Adili R, Noble J, Hoenerhoff MJ, Holinstat M, Eniola-Adefeso O. Neutrophil-Particle Interactions in Blood Circulation Drive Particle Clearance and Alter Neutrophil Responses in Acute Inflammation. ACS NANO 2017; 11:10797-10807. [PMID: 29028303 PMCID: PMC5709153 DOI: 10.1021/acsnano.7b03190] [Citation(s) in RCA: 57] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/14/2023]
Abstract
Although nano- and microparticle therapeutics have been studied for a range of drug delivery applications, the presence of these particles in blood flow may have considerable and understudied consequences to circulating leukocytes, especially neutrophils, which are the largest human leukocyte population. The objective of this work was to establish if particulate drug carriers in circulation interfere with normal neutrophil adhesion and migration. Circulating blood neutrophils in vivo were found to be capable of rapidly binding and sequestering injected carboxylate-modified particles of both 2 and 0.5 μm diameter within the bloodstream. These neutrophil-particle associations within the vasculature were found to suppress neutrophil interactions with an inflamed mesentery vascular wall and hindered neutrophil adhesion. Furthermore, in a model of acute lung injury, intravenously administered drug-free particles reduced normal neutrophil accumulation in the airways of C57BL/6 mice between 52% and 60% versus particle-free mice and between 93% and 98% in BALB/c mice. This suppressed neutrophil migration resulted from particle-induced neutrophil diversion to the liver. These data indicate a considerable acute interaction between injected particles and circulating neutrophils that can drive variations in neutrophil function during inflammation and implicate neutrophil involvement in the clearance process of intravenously injected particle therapeutics. Such an understanding will be critical toward both enhancing designs of drug delivery carriers and developing effective therapeutic interventions in diseases where neutrophils have been implicated.
Collapse
Affiliation(s)
- Catherine A. Fromen
- Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109
| | - William J. Kelley
- Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109
| | - Margaret B. Fish
- Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109
| | - Reheman Adili
- Department of Pharmacology, University of Michigan, Ann Arbor, MI 48109
| | - Jeffery Noble
- Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109
| | - Mark J. Hoenerhoff
- In Vivo Animal Core, Unit for Laboratory Animal Medicine, University of Michigan, Ann Arbor, MI 48109
| | - Michael Holinstat
- Department of Pharmacology, University of Michigan, Ann Arbor, MI 48109
- Department of Cardiovascular Medicine, Samuel and Jean Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI 48109
| | - Omolola Eniola-Adefeso
- Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109
- Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109
| |
Collapse
|
40
|
Yusuf A, Brophy A, Gorey B, Casey A. Liposomal encapsulation of silver nanoparticles enhances cytotoxicity and causes induction of reactive oxygen species-independent apoptosis. J Appl Toxicol 2017; 38:616-627. [DOI: 10.1002/jat.3566] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2017] [Revised: 10/09/2017] [Accepted: 10/19/2017] [Indexed: 12/16/2022]
Affiliation(s)
- A. Yusuf
- School of Physics; Dublin Institute of Technology; Kevin Street Dublin 8 Ireland
- Nanolab Research Centre, FOCAS Research Institute; Dublin Institute of Technology; Kevin Street Dublin 8 Ireland
| | - A. Brophy
- Nanolab Research Centre, FOCAS Research Institute; Dublin Institute of Technology; Kevin Street Dublin 8 Ireland
| | - B. Gorey
- Nanolab Research Centre, FOCAS Research Institute; Dublin Institute of Technology; Kevin Street Dublin 8 Ireland
| | - A. Casey
- School of Physics; Dublin Institute of Technology; Kevin Street Dublin 8 Ireland
- Nanolab Research Centre, FOCAS Research Institute; Dublin Institute of Technology; Kevin Street Dublin 8 Ireland
| |
Collapse
|
41
|
Vogus DR, Evans MA, Pusuluri A, Barajas A, Zhang M, Krishnan V, Nowak M, Menegatti S, Helgeson ME, Squires TM, Mitragotri S. A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer. J Control Release 2017; 267:191-202. [PMID: 28823957 DOI: 10.1016/j.jconrel.2017.08.016] [Citation(s) in RCA: 62] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2017] [Revised: 08/10/2017] [Accepted: 08/15/2017] [Indexed: 12/31/2022]
Abstract
Combination chemotherapy is commonly used to treat advanced breast cancer. However, treatment success is often limited due to systemic toxicity. To improve therapeutic efficacy, polymer drug conjugates carrying synergistic pairs of chemotherapy drugs can be used to reduce drug administration dose. Here, we systematically evaluated the effect of temporal scheduling of doxorubicin (DOX) and gemcitabine (GEM) on drug synergy. Hyaluronic acid (HA) drug conjugates with distinct linkers conjugating both DOX and GEM were synthesized to control relative release kinetics of each drug. We show that polymer conjugates that release GEM faster than DOX are more effective at killing triple negative breast cancer cells in vitro. We further show that the optimal dual drug conjugate more effectively inhibits the growth of an aggressive, orthotopic 4T1 tumor model in vivo than free DOX and GEM and the single drug HA conjugates. The dual drug HA conjugate can inhibit 4T1 tumor growth in vivo during treatment through both intravenous and non-local subcutaneous injections. These results emphasize the importance of understanding the effect release rates have on the efficacy of synergistic drug carriers and motivate the use of HA as a delivery platform for multiple cancer types.
Collapse
Affiliation(s)
- Douglas R Vogus
- Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA 93106, United States
| | - Michael A Evans
- Department of Chemistry, University of California, Santa Barbara, Santa Barbara, CA 93106, United States
| | - Anusha Pusuluri
- Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA 93106, United States
| | - Alexandra Barajas
- Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA 93106, United States
| | - Mengwen Zhang
- Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA 93106, United States
| | - Vinu Krishnan
- Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA 93106, United States
| | - Maksymilian Nowak
- Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA 93106, United States
| | - Stefano Menegatti
- Department of Chemistry, University of California, Santa Barbara, Santa Barbara, CA 93106, United States
| | - Matthew E Helgeson
- Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA 93106, United States
| | - Todd M Squires
- Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA 93106, United States
| | - Samir Mitragotri
- Department of Chemical Engineering, University of California, Santa Barbara, Santa Barbara, CA 93106, United States; Center for Bioengineering, University of California, Santa Barbara, Santa Barbara, CA 93106, United States.
| |
Collapse
|
42
|
Naeem S, Viswanathan G, Misran MB. Liposomes as colloidal nanovehicles: on the road to success in intravenous drug delivery. REV CHEM ENG 2017. [DOI: 10.1515/revce-2016-0018] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Abstract
The advancement of research in colloidal systems has led to the increased application of this technology in more effective and targeted drug delivery. Nanotechnology enables control over functionality parameters and allows innovations in biodegradable, biocompatible, and stimuli-responsive delivery systems. The first closed bilayer phospholipid system, the liposome system, has been making steady progress over five decades of extensive research and has been efficient in achieving many desirable parameters such as remote drug loading, size-controlling measures, longer circulation half-lives, and triggered release. Liposome-mediated drug delivery has been successful in overcoming obstacles to cellular and tissue uptake of drugs with improved biodistribution in vitro and in vivo. These colloidal nanovehicles have moved on from a mere concept to clinical applications in various drug delivery systems for antifungal, antibiotic, and anticancer drugs.
Collapse
Affiliation(s)
- Sumaira Naeem
- Department of Chemistry , Faculty of Science, University of Malaya , 50603 Kuala Lumpur , Malaysia
- Department of Chemistry, Faculty of Science , University of Gujrat , Gujrat , Pakistan
| | - Geetha Viswanathan
- Department of Pharmacy , Faculty of Medicine Building, University of Malaya , 50603 Kuala Lumpur , Malaysia
| | - Misni Bin Misran
- Department of Chemistry , Faculty of Science, University of Malaya , 50603 Kuala Lumpur , Malaysia
| |
Collapse
|
43
|
Zhu H, Wang Y, Hussain A, Zhang Z, Shen Y, Guo S. Nanodiamond mediated co-delivery of doxorubicin and malaridine to maximize synergistic anti-tumor effects on multi-drug resistant MCF-7/ADR cells. J Mater Chem B 2017; 5:3531-3540. [DOI: 10.1039/c7tb00449d] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Novel nanodiamond based nanoparticle co-loading of doxorubicin and malaridine with pH-responsive co-release properties was developed for maximizing synergistic anti-tumor effects on multi-drug resistant MCF-7/ADR cells.
Collapse
Affiliation(s)
- Hao Zhu
- School of Pharmacy
- Shanghai Jiao Tong University
- Shanghai
- China
| | - Yun Wang
- School of Pharmacy
- Shanghai Jiao Tong University
- Shanghai
- China
| | - Abid Hussain
- School of Pharmacy
- Shanghai Jiao Tong University
- Shanghai
- China
| | - Zhipeng Zhang
- School of Pharmacy
- Shanghai Jiao Tong University
- Shanghai
- China
| | - Yuanyuan Shen
- School of Pharmacy
- Shanghai Jiao Tong University
- Shanghai
- China
| | - Shengrong Guo
- School of Pharmacy
- Shanghai Jiao Tong University
- Shanghai
- China
| |
Collapse
|
44
|
Marciello M, Pellico J, Fernandez-Barahona I, Herranz F, Ruiz-Cabello J, Filice M. Recent advances in the preparation and application of multifunctional iron oxide and liposome-based nanosystems for multimodal diagnosis and therapy. Interface Focus 2016; 6:20160055. [PMID: 27920894 PMCID: PMC5071816 DOI: 10.1098/rsfs.2016.0055] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Nowadays, thanks to the successful discoveries in the biomedical field achieved in the last two decades, a deeper understanding about the complexity of mechanistic aspects of different pathological processes has been obtained. As a consequence, even the standard therapeutic protocols have undergone a vast redesign. In fact, the awareness about the necessity to progress towards a combined multitherapy in order to potentially increase the final healing chances has become a reality. One of the crucial elements of this novel approach is that large amounts of detailed information are highly needed and in vivo imaging techniques represent one of the most powerful tools to visualize and monitor the pathological state of the patient. To this scope, due to their unique features, nanostructured materials have emerged as attractive elements for the development of multifunctional tools for diagnosis and therapy. Hence, in this review, the most recent and relevant advances achieved by applying multifunctional nanostructures in multimodal theranosis of different diseases will be discussed. In more detail, the preparation and application of single multifunctional nano-radiotracers based on iron oxides and enabling PET/MRI dual imaging will be firstly detailed. After that, especially considering their highly promising clinical potential, the preparation and application of multifunctional liposomes useful for multimodal imaging and therapy will be reviewed. In both cases, a special focus will be set on the application of such a multifunctional nanocarriers in cancer as well as cardiovascular diseases.
Collapse
Affiliation(s)
- Marzia Marciello
- Department of Biomaterials and Bioinspired Material, Materials Science Institute of Madrid (ICMM-CSIC), Sor Juana Inés de la Cruz 3, Cantoblanco, Madrid, Spain
| | - Juan Pellico
- Advanced Imaging Unit, Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), CIBER de Enfermedades Respiratorias, C/Melchor Fernández-Almagro 3, 28029 Madrid, Spain
| | - Irene Fernandez-Barahona
- Advanced Imaging Unit, Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), CIBER de Enfermedades Respiratorias, C/Melchor Fernández-Almagro 3, 28029 Madrid, Spain
| | - Fernando Herranz
- Advanced Imaging Unit, Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), CIBER de Enfermedades Respiratorias, C/Melchor Fernández-Almagro 3, 28029 Madrid, Spain
- Departamento de Bioingeniería e Ingeniería Aeroespacial, Universidad Carlos III de Madrid, Madrid, Spain
| | - Jesus Ruiz-Cabello
- Advanced Imaging Unit, Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), CIBER de Enfermedades Respiratorias, C/Melchor Fernández-Almagro 3, 28029 Madrid, Spain
- Universidad Complutense de Madrid, Plaza Ramón y Cajal, 28040 Madrid, Spain
| | - Marco Filice
- Advanced Imaging Unit, Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), CIBER de Enfermedades Respiratorias, C/Melchor Fernández-Almagro 3, 28029 Madrid, Spain
| |
Collapse
|
45
|
Wojnilowicz M, Tortora M, Bobay BG, Santiso E, Caruso M, Micheli L, Venanzi M, Menegatti S, Cavalieri F. A combined approach for predicting the cytotoxic effect of drug-nanoaggregates. J Mater Chem B 2016; 4:6516-6523. [PMID: 32263696 DOI: 10.1039/c6tb02105k] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
We present a combined spectroscopic and computational approach aimed to elucidate the mechanism of formation and activity of etoposide nanoaggregates upon release from dextran-etoposide conjugates. Etoposide is an anticancer drug that inhibits cell growth by blocking Topoisomerase II, the key enzyme involved in re-ligation of the DNA chains during the replication process. In silico and spectroscopic analysis indicate that released etoposide nanoaggregates have a different structure, stability, and bioactivity, which depend on the pH experienced during the release. Molecular dynamics simulation and in silico docking of etoposide dimers suggest that the aggregation phenomena inhibit etoposide bioactivity, yet without drastically preventing Topoisomerase II binding. We correlated the diminished cytotoxic activity exerted by dextran-etoposide conjugates on the A549 lung cancer cells, compared to the free drug, to the formation and stability of drug nanoaggregates.
Collapse
Affiliation(s)
- M Wojnilowicz
- Department of Chemical and Biomolecular Engineering, The University of Melbourne, Parkville, Melbourne, Victoria 3010, Australia.
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Sun J, Song Y, Lu M, Lin X, Liu Y, Zhou S, Su Y, Deng Y. Evaluation of the antitumor effect of dexamethasone palmitate and doxorubicin co-loaded liposomes modified with a sialic acid–octadecylamine conjugate. Eur J Pharm Sci 2016; 93:177-83. [DOI: 10.1016/j.ejps.2016.08.029] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2016] [Revised: 08/06/2016] [Accepted: 08/13/2016] [Indexed: 02/07/2023]
|